S
Silo Pharma, Inc.
SILOCIK 0001514183NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31
Period
FY 2025
Revenue
$72.1K
Net Income
$-4.23M
Total Assets
$7.61M
Equity
$6.31M
Shares Out
16.27M
Op. Cash Flow
$-4.66M
Business
Silo Pharma is a developmental-stage biopharmaceutical company focused on novel therapeutics for PTSD, anxiety disorders, fibromyalgia, and CNS diseases using conventional drugs and psychedelic formulations. Lead programs include SPC-15 (intranasal PTSD treatment), SP-26 (ketamine implant for fibromyalgia), SPC-14 (Alzheimer's), and SPU-16 (CNS peptide for multiple sclerosis). The company licenses intellectual property from universities including Columbia and University of Maryland, Baltimore, and holds cryptocurrency treasury assets.
Summary from 10-K filed 2026-03-27
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| LICENSE FEE REVENUE | 72,102 | 72,102 | 72,102 | 72,102 | — | |
| COST OF REVENUES | 44,295 | 5,838 | 5,838 | 5,838 | 5,004 | |
| GROSS PROFIT | 27,807 | 66,264 | 66,264 | 66,264 | 66,260 | |
| Compensation expense | 830,322 | 906,773 | — | — | — | |
| Professional fees | 1 | 1 | 2 | 1 | 2 | |
| Research and development | 2 | 2 | 845,092 | 1 | 693,910 | |
| Other selling, general and administrative expenses | 258,709 | 298,284 | — | — | — | |
| Total operating expenses | 4 | 5 | 4 | 4 | 3 | |
| LOSS FROM OPERATIONS | −4 | −5 | −4 | −4 | −3 | |
| Interest and dividend income, net | 193,912 | 333,165 | 398,530 | 72,637 | — | |
| Interest expense | −37,302 | −5,084 | −4,869 | — | — | |
| Net realized gain (loss) on short-term investments | 3,911 | −1,025 | — | −104,700 | — | |
| Unrealized loss on short term investments | −3,240 | — | −3,118 | — | — | |
| Staking income on crypto assets | 207 | — | — | — | — | |
| Unrealized loss on crypto assets, at fair value | −64,608 | — | — | — | — | |
| Impairment loss on crypto assets, at cost | −39,916 | — | — | — | — | |
| Foreign currency transaction loss | — | −14,242 | — | — | — | |
| Total other income , net | 52,964 | 312,814 | 224,509 | −279,732 | 7 | |
| LOSS BEFORE PROVISION FOR INCOME TAXES | −4 | −4 | −4 | −4 | 4 | |
| Provision for income taxes | — | — | — | — | −24,876 | |
| NET LOSS | −4 | −4 | −4 | −4 | 4 | |
| Unrealized gain on short-term debt investments | 3,409 | 8,646 | −6,227 | — | — | |
| Total comprehensive loss | −4 | −4 | −4 | −4 | — | |
| Basic (in Dollars per share) | −0.5 | −1.19 | −1.2 | — | 0.04 | |
| Diluted (in Dollars per share) | −0.5 | −1.19 | −1.2 | — | 0.04 | |
| Basic (in Shares) | 8 | 4 | 3 | 2 | 2 | |
| Diluted (in Shares) | 8 | 4 | 3 | 2 | 2 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 4 | 4 | 11 | 10 | |
| Short-term investments, at fair value | 2 | 3 | 4 | — | — | |
| Crypto assets, at fair value | 221,817 | — | — | — | — | |
| Crypto assets, at cost | 98,584 | — | — | — | — | |
| Prepaid expenses and other current assets | 208,559 | 30,957 | 15,970 | 135,894 | 145,324 | |
| Total Current Assets | 7 | 7 | 8 | 12 | 10 | |
| Prepaid expenses and other assets - non-current | — | 59,145 | 64,983 | — | — | |
| Intangible assets, net | 217,375 | 241,215 | — | — | — | |
| Total Long-Term Assets | 217,375 | 300,360 | 64,983 | — | — | |
| Total Assets | 8 | 7 | 8 | 12 | 10 | |
| Accounts payable and accrued expenses | 578,081 | 2 | 703,488 | 364,216 | 417,937 | |
| Deferred revenue - current portion | 72,102 | 72,102 | 72,102 | — | — | |
| Total Current Liabilities | 650,183 | 2 | 775,590 | 436,318 | 490,039 | |
| Deferred revenue - long-term portion | 649,476 | 721,578 | 793,680 | — | — | |
| Total Long-Term Liabilities | 649,476 | 721,578 | 793,680 | 865,782 | 937,884 | |
| Total Liabilities | 1 | 2 | 2 | 1 | 1 | |
| Commitment and Contingencies (see Note 8) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value, 5,000,000 shares authorized: none designated as of December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.0001 par value, 100,000,000 shares authorized; 13,318,273 and 4,484,456 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1,332 | 449 | 316 | 316 | 197 | |
| Additional paid-in capital | 26 | 20 | 18 | 18 | 12 | |
| Accumulated other comprehensive income | 5,828 | 2,419 | −6,227 | — | — | |
| Accumulated deficit | −19 | −15 | −11 | −7 | −3 | |
| Total Stockholders Equity | 6 | 5 | 6 | 10 | 9 | |
| Total Liabilities and Stockholders Equity | 8 | 7 | 8 | 12 | 10 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Amortization expense | 11,440 | 6,185 | — | — | — | |
| Staking income on crypto assets | −207 | — | — | — | — | |
| Impairment loss on crypto assets, at cost | 39,916 | — | — | — | — | |
| Stock-based compensation | 117,021 | — | — | — | — | |
| Common stock issued for acquired technology expensed | 518,225 | — | — | — | — | |
| Prepaid expenses and other current assets | −118,457 | −9,149 | 35,695 | 55,335 | — | |
| Accounts payable and accrued expenses | −993,414 | 633,007 | 339,272 | −53,721 | 291,050 | |
| Deferred revenue | −72,102 | −72,102 | −72,102 | — | — | |
| NET CASH USED IN OPERATING ACTIVITIES | −5 | −4 | −3 | −3 | −2 | |
| Proceeds from the sale of short-term debt investments | 1 | 1 | — | — | — | |
| Purchases of short-term investments | −96,712 | −175,543 | −4 | — | — | |
| Purchases of crypto assets | −574,920 | — | — | — | — | |
| NET CASH PROVIDED BY INVESTING ACTIVITIES | 644,021 | 973,777 | −4 | 86,707 | 7 | |
| Net proceeds from sale of common stock and pre-funded warrants | 4 | 2 | — | — | — | |
| Net proceeds from sale of common stock and warrants | — | 2 | — | 5 | — | |
| Proceeds from exercise of warrants, net of offering costs | 1 | 3 | — | — | — | |
| Purchase of treasury stock | — | −173,113 | −471,121 | — | — | |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 5 | 3 | −471,121 | 5 | 4 | |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 842,901 | 381,491 | −8 | 2 | 9 | |
| Interest | 37,302 | 5,084 | 4,869 | 2,199 | — | |
| Income taxes | — | — | — | 25,159 | — | |
| Unrealized gain on short-term debt investments | 3,409 | 8,646 | — | — | — | |
| Crypto assets, at fair value used to acquire short-term investments | 150,202 | — | — | — | — | |
| Conversion crypto assets, at fair value for crypto assets, at cost for liquid staking activities | 138,500 | — | — | — | — | |
| Intangible assets acquired in exchange for accounts payable and accrued expenses | — | 247,400 | — | — | — | |
| Decrease in intangible assets and accounts payable and accrued expenses | 12,400 | — | — | — | — | |
| Cancellation of treasury stock | — | 644,234 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Silo Pharma, Inc.'s CIK number?
Silo Pharma, Inc.'s SEC CIK number is 0001514183 (1514183). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Silo Pharma, Inc.'s SEC filings?
All of Silo Pharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.